Skip to main content
. 2014 Jul 31;5(16):7183–7197. doi: 10.18632/oncotarget.2293

Fig.3. The association of Apollon expression with the chemotherapeutic response and survival outcome in ESCC patients undergone cisplatin-based chemotherapy.

Fig.3

(A-B) Typical patterns of Apollon staining in tumor tissues of 70 ESCC patients with differential chemotherapeutic response. The esophageal cancers with complete response (CR)/partial response (PR) (A) responses to cisplatin-based chemotherapy expressed lower levels, whereas those with stable disease (SD)/progressive disease (PD) (B) responses expressed higher levels of Apollon. (C) Scores of immunochemistry staining of Apollon in 70 ESCC patients with different chemotherapeutic response. **P < 0.01. (D) Kaplan-Meier analysis of overall survival (OS) for Apollon expression in 70 ESCC patients undergone cisplatin-based chemotherapy.